References
- Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5
- Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581–92
- American Joint Committee of Cancer. AJCC Cancer Staging Handbook. 6th ed. New York: Springer-Verlag; 2002.
- Vokes EE, Weichselbaum RR, Lippman S, Hong WK. Head and neck cancer. N Engl J Med 1993; 328: 184–94
- Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Grouppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994; 86: 265–72
- Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, et al. Hyperfraccionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338: 1798–804
- Merlano M, Benasso M, Corvo R, Rosso R, Vitale V, Blengio F, et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996; 88: 583–9
- Wendt TG, Grabenbauer GG, Rödel CM, Thiel HJ, Aydin H, Rohloff R, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 1998; 16: 1318–24
- Pignon JP, Bourihis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analysis of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355(9208)949–55
- Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med ;345:1890–900. Erratum in: N Engl J Med ;346 2001; 2002: 788
- Vermorken JB, Remenar E, Van Herpen C, Germa Lluch J, Stewart S, Gorlia T, et al A randomized phase III multicenter trial of neoadjuvant Docetaxel plus Cisplatin plus 5-Fluorouracil versus neoadjuvant Cisplatin plus 5-Fluorouracil in patients with locally advanced unresectable squamous cell carcinoma of the head and neck. Proc ASCO 2004. Abst 5508.
- Posner MR. Docetaxel added to induction therapy in head and neck cancer. Scientific Special Session. ASCO-2006.
- Calais G, Pointreau Y, Alfonsi M, Sire C, Tuchais C, J. Tortochaux, et al Randomized phase III trial comparing induction chemotherapy using Cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01. Proc ASCO 2006. Abst 5506.
- Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, et al. Phase III study comparing Cisplatin plus 5-Fluorouracil to Paclitaxel, Cisplatin and 5-Fluoruracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. JCO 2005; 23: 8636–45
- Hitt R, Grau J, Lopez-Pousa A, Berrocal A, Sastre J, Belon J, et al Phase II/III trial of induction chemotherapy (ICT) with Cisplatin/5-Fluorouracil (PF) vs. Docetaxel (T) plus PF (TPF) followed by chemoradiotherapy (CRT) vs. CRT for unresectable locally advanced head and neck cancer (LAHNC). Proc ASCO 2005. Abst 5578.